Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment.
From: New York University Cancer Institute, New York University Medical School, 160 E 34th St, 8th Floor, New York, NY 10016, USA. anna.ferrari@nyumc.org
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publish Date: Jul 2006
- ISSN: 1527-7755
- Volume: 24
- Issue: 19
- Pages: 3081-8
- Medium: Internet
- Language: English
- Citation (JAMA): Ferrari Anna C, Stone Nelson N, Kurek Ralf, et al. Molecular Load of Pathologically Occult Metastases in Pelvic Lymph Nodes is an Independent Prognostic Marker of Biochemical Failure After Localized Prostate Cancer Treatment.. J. Clin. Oncol. Jul 2006;24:3081-8
Abstract
PURPOSE: Thirty percent of patients treated with curative intent for localized prostate cancer (PC) experience biochemical recurrence (BCR) with rising serum prostate-specific antigen (sPSA), and of these, approximately 50% succumb to progressive disease. More discriminatory staging procedures are needed to identify occult micrometastases that spawn BCR. PATIENTS AND METHODS: PSA mRNA copies in pathologically normal pelvic lymph nodes (N0-PLN) from 341 localized PC patients were quantified by real-time reverse-transcriptase polymerase chain reaction. Based on comparisons with normal lymph nodes and PLN with metastases and on normalization to 5 x 10(6) glyceraldehyde-3’-phosphate dehydrogenase mRNA copies, normalized PSA copies (PSA-N) and a threshold of PSA-N 100 or more were selected for continuous and categorical multivariate analyses of biochemical failure-free survival (BFFS) compared with established risk factors. RESULTS: At median follow-up of 4 years, the BFFS of patients with PSA-N 100 or more versus PSA-N less than 100 was 55% and 77% (P = .0002), respectively. The effect was greatest for sPSA greater than 20 ng/mL, 25% versus 60% (P = .014), Gleason score 8 or higher, 21% versus 66% (P = .0002), stage T3c, 18% versus 64% (P = .001), and high-risk group (50% v 72%; P = .05). By continuous analysis PSA-N was an independent prognostic marker for BCR (P = .049) with a hazard ratio of 1.25 (95% CI, 1.001 to 1.57). By categorical analysis, PSA-N 100 or more was an independent variable (P = .021) with a relative risk of 1.98 (95% CI, 1.11 to 3.55) for BCR compared with PSA-N less than 100. CONCLUSION: PSA-N 100 or more is a new, independent molecular staging criterion for localized PC that identifies high-risk group patients with clinically relevant occult micrometastases in N0-PLN, who may benefit from additional therapy to prevent BCR.
Mesh Headings (Keywords): Aged, Disease Progression, Humans, Lymphatic Metastasis, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Prostate-Specific Antigen, Prostatic Neoplasms, RNA, Messenger, Reverse Transcriptase Polymerase Chain Reaction, Risk Factors, Sensitivity and Specificity, Treatment Outcome, Tumor Markers, Biological
Check for Full Text / PubMed Unique Identifier (PMID): 16809733
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.